In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Stuckey, Daniel J ^a,b   Carr, Carolyn A ^a   Camelliti, Patrizia ^b   Tyler, Damian J ^a   Davies, Kay E ^a   Clarke, Kieran ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; GADOLINIUM; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLE; DISEASE COURSE; HEART DISEASE; HEART FUNCTION TEST; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE FAILURE; IN VIVO STUDY; MALE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINATAL PERIOD; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECT; FIBROSIS; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART RIGHT VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; TIME;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOBUTAMINE; FIBROSIS; GADOLINIUM; HEART; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHIES; MYOCARDIUM; STRESS, PHYSIOLOGICAL; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84855315951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028569     Document Type: Article

References (51)

1. Finsterer J, Stollberger C, (2003) The heart in human dystrophinopathies. Cardiology 99: 1-19.
2. AMERICAN-ACADEMY-OF-PEDIATRICS (2005) Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 116: 1569-1573.
3. Lapidos KA, Kakkar R, McNally EM, (2004) The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94: 1023-1031.
4. Fayssoil A, Nardi O, Orlikowski D, Annane D, (2010) Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail Rev 15: 103-107.
5. Au CG, Butler TL, Sherwood MC, Egan JR, North KN, et al. (2010) Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 92: 57-65.
6. Crisp A, Yin H, Goyenvalle A, Betts C, Moulton HM, et al. (2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet 20: 413-421.
7. Li W, Liu W, Zhong J, Yu X, (2009) Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging. J Cardiovasc Magn Reson 11: 40-51.
8. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, et al. (2004) Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 14: 491-496.
9. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, et al. (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580.
10. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, et al. (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352: 536-539.
11. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, et al. (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384: 349-353.
12. Van Erp C, Loch D, Laws N, Trebbin A, Hoey AJ, (2010) Timeline of cardiac dystrophy in 3-18-month-old MDX mice. Muscle Nerve 42: 504-513.
13. Zhang W, ten Hove M, Schneider JE, Stuckey DJ, Sebag-Montefiore L, et al. (2008) Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: an MRI and MRS study. J Mol Cell Cardiol 45: 754-760.
14. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, et al. (1999) Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 31: 1857-1862.
15. Bostick B, Yue Y, Duan D, (2010) Gender influences cardiac function in the mdx model of Duchenne cardiomyopathy. Muscle Nerve 42: 600-603.
16. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177.
17. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
18. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, et al. (2007) Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 1086-1092.
19. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A 105: 14814-14819.
20. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
21. Mavrogeni S, Papavasiliou A, Spargias K, Constandoulakis P, Papadopoulos G, et al. (2010) Myocardial inflammation in Duchenne Muscular Dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol 10: 33.
22. Yilmaz A, Gdynia HJ, Baccouche H, Mahrholdt H, Meinhardt G, et al. (2008) Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson 10: 50.
23. Angelini C, Fanin M, Freda MP, Martinello F, Miorin M, et al. (1996) Prognostic factors in mild dystrophinopathies. J Neurol Sci 142: 70-78.
24. Silva MC, Meira ZM, Gurgel Giannetti J, da Silva MM, Campos AF, et al. (2007) Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 49: 1874-1879.
25. Barison A, Aquaro GD, Passino C, Falorni M, Balbarini A, et al. (2009) Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier. J Neurol 256: 283-284.
26. Guillaume MD, Phoon CK, Chun AJ, Srichai MB, (2008) Delayed enhancement cardiac magnetic resonance imaging in a patient with Duchenne muscular dystrophy. Tex Heart Inst J 35: 367-368.
27. Varghese A, Pennell DJ, (2004) Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy. Heart 90: e59.
28. Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, et al. (2009) Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc Imaging 25: 57-63.
29. Schneider JE, Cassidy PJ, Lygate C, Tyler DJ, Wiesmann F, et al. (2003) Fast, high-resolution in vivo cine magnetic resonance imaging in normal and failing mouse hearts on a vertical 11.7 T system. J Magn Reson Imaging 18: 691-701.
30. Stuckey DJ, Carr CA, Tyler DJ, Aasum E, Clarke K, (2008) Novel MRI method to detect altered left ventricular ejection and filling patterns in rodent models of disease. Magn Reson Med 60: 582-587.
31. Protti A, Sirker A, Shah AM, Botnar R, (2010) Late gadolinium enhancement of acute myocardial infarction in mice at 7T: cine-FLASH versus inversion recovery. J Magn Reson Imaging 32: 878-886.
32. Carr CA, Stuckey DJ, Tatton L, Tyler DJ, Hale SJ, et al. (2008) Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study. Am J Physiol Heart Circ Physiol 295: H533-542.
33. Wiesmann F, Frydrychowicz A, Rautenberg J, Illinger R, Rommel E, et al. (2002) Analysis of right ventricular function in healthy mice and a murine model of heart failure by in vivo MRI. Am J Physiol Heart Circ Physiol 283: H1065-1071.
34. Stuckey DJ, Carr CA, Tyler DJ, Clarke K, (2008) Cine-MRI versus two-dimensional echocardiography to measure in vivo left ventricular function in rat heart. NMR Biomed 21: 765-772.
35. Bellenger NG, Marcus NJ, Rajappan K, Yacoub M, Banner NR, et al. (2002) Comparison of techniques for the measurement of left ventricular function following cardiac transplantation. J Cardiovasc Magn Reson 4: 255-263.
36. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, et al. (2001) Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. Faseb J 15: 1655-1657.
37. Baer FM, Theissen P, Schneider CA, Voth E, Sechtem U, et al. (1998) Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 31: 1040-1048.
38. Song W, Dyer E, Stuckey D, Leung MC, Memo M, et al. (2010) Investigation of a transgenic mouse model of familial dilated cardiomyopathy. J Mol Cell Cardiol 49: 380-389.
39. Wiesmann F, Ruff J, Engelhardt S, Hein L, Dienesch C, et al. (2001) Dobutamine-stress magnetic resonance microimaging in mice: acute changes of cardiac geometry and function in normal and failing murine hearts. Circ Res 88: 563-569.
40. Harpole DH Jr, Jones RH, (1992) Left ventricular function under stress before and after myocardial revascularization. Am Heart J 124: 273-279.
41. O'Sullivan CA, Duncan A, Daly C, Li W, Oldershaw P, et al. (2005) Dobutamine stress-induced ischemic right ventricular dysfunction and its relation to cardiac output in patients with three-vessel coronary artery disease with angina-like symptoms. Am J Cardiol 96: 622-627.
42. Fujii Y, Toyooka H, Ebata T, Amaha K, (1993) Contractility of fatigued diaphragm is improved by dobutamine. Can J Anaesth 40: 453-458.
43. Bohl S, Wassmuth R, Abdel-Aty H, Rudolph A, Messroghli D, et al. (2008) Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 24: 597-607.
44. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, et al. (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56: 875-887.
45. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, et al. (2005) Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 45: 98-103.
46. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, et al. (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343: 1445-1453.
47. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, et al. (2001) Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 104: 1101-1107.
48. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, et al. (2006) Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 113: 2733-2743.
49. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, et al. (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56: 867-874.
50. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, et al. (2006) Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48: 1977-1985.
51. Bohl S, Lygate CA, Barnes H, Medway D, Stork LA, et al. (2009) Advanced methods for quantification of infarct size in mice using three-dimensional high-field late gadolinium enhancement MRI. Am J Physiol Heart Circ Physiol 296: H1200-1208.